Current Issue Article:

Advances in the Management of Multiple Sclerosis: A Closer Look at Novel Therapies

FDA APPROVED FOR INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS. Significantly more patients with intermediate-2 — risk or high-risk myelofibrosis receiving Jakafi® (ruxolitinib) achieved the primary end point compared with placebo (COMFORT-I*) or best available therapy † (COMFORT-II‡) 1-3.

Click Here…

Managed Care eNews

‘Dishing’ out a new test to improve breast cancer treatment
Multibrief Exclusive
Excluding cancers of the skin, breast cancer is the most common cancer among women in the United States, accounting for 29 percent of newly diagnosed cancers. Breast cancer incidence and death rates generally increase with age, and 79 percent of new cases and 88 percent of breast cancer deaths occur in women 50 years of age and older.

Click Here…

Genomics Biotech and Emerging Medical Technologies

Massive study reveals schizophrenia’s genetic roots
Scientific American
Schizophrenia is a distressing disorder involving hallucinations, delusions, paranoia and agitation. It affects around one in 100 people in the U.S., with symptoms usually first appearing between the ages of 16 and 30. Its causes have long been debated, particularly regarding whether genetics plays a role. It is known to be highly heritable, but small sample sizes and other methodology hurdles stymied early attempts to discern a genetic link.

Click Here…

Prevention, Lifestyle & Wellness

The sneaky cause of your sugar cravings
Yahoo Health
Sugar can’t catch a break these days. With everyone from from HBO comedian John Oliver to Yahoo’s Global New Anchor Katie Couric bashing sugar’s vice-like grip on the modern diet, more and more people are deciding to ditch it. The problem? It’s really, really difficult.

Click Here…